Study to Assess the Effect of Multi-herb Formulae and an Ashwagandha Root Formula on the Modulation of the Stress and Related Symptoms

A Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Assess the Effect of Multi-herb Formulae VL-G-A57 and an Ashwagandha Root Formula (VL-G-E12) on the Modulation of the Hypothalamic-pituitary-adrenal Axis (HPA Axis) and Related Symptoms

Two unique proprietary formulations of adaptogens VL-G-E12 formulation and an herbal blend containing VL-G-A57 is one of the most well-known adaptogens that has been used for years to enhance positive mood states, deepen sleep, and improve memory. The product has been proven to have a role in improving depression, enhancing work performance, eliminating fatigue and treating symptoms of asthenia subsequent to intense physical and psychological stress. The extract was tested on antidepressant, adaptogenic, anxiolytic, nociceptive and locomotor activities at doses of 10, 15 and 20 mg/kg, using predictive behavioral tests and animal models. The results show that this product extract significantly, but not dose-dependently, induced antidepressant-like, adaptogenic, anxiolytic-like and stimulating effects in mice. Studies reveal that this shrub has antimicrobial (including antibacterial, antiviral, antifungal, antiprotozoal, antimalarial, anthelmintic), anti-inflammatory, anti-diabetic, anti-hypercholesterolemia, anti-hypertensive, anti-carcinogenic, and immunomodulatory effect.The aim of the current study is to assess the adaptogenic effects of two potential investigational products VL-G-A57 and VL-G-E12 Their adaptogenic effect shall be investigated by assessing several clinical symptoms of HPA axis dysfunction such as stress, anxiety, sleep quality, fatigue, mood etc.

Study Overview

• Status: Completed
• Conditions: Stress
• Intervention / Treatment: Other: VL-G-A57; Other: VL-G-E12; Other: Placebo

• Study Type: Interventional
• Enrollment (Actual): 186
• Phase: Not Applicable

Contacts and Locations

Study Locations

• India
  • Maharashtra
    • Mumbai, Maharashtra, India, 400059
      • Stress Test Clinic
    • Mumbai, Maharashtra, India, 400053
      • Vedic Lifesciences PVT LTD
    • Mumbai, Maharashtra, India, 400067
      • Shree Polyclinic
    • Mumbai, Maharashtra, India, 400068
      • The Kewalramani Clini
    • Pālghar, Maharashtra, India, 401209
      • Dr Chandrakant Mishra clinic

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria

1. Male and female subjects ≥18 and ≤ 65 years' old with active lifestyle, moderate physical activity level as per International Physical Activity Questionnaire - Short Form (IPAQ - SF)
2. BMI: 18 to 29.9 kg/m2
3. RSQ-W (Restorative Sleep Questionnaire-weekly version) score less than or equal to 50
4. PSS scores ranging from 27-40
5. All participants will be encouraged to not make any major lifestyle changes during the study period.
6. They will be informed that any major changes may result in exclusion from the study.
7. Participants willing to provide written informed consent.

Exclusion Criteria

1. Subjects with a medical history of heart disease, respiratory disorders, metabolic or lifestyle disorders, seizure disorders, or other chronic health conditions requiring medication were excluded.
2. Individuals who currently, or in the past 6 months suffered from any diagnosable mental-health disorder (as assessed by the Mini International Neuropsychiatric Interview 5.0.01 ) or were taking apsychotropic medication or other herbal preparation were also excluded from participating in the study.
3. Subjects with a blood pressure range of systolic ≥ 140 mm Hg and diastolic ≥ 90 mm Hg.
4. Subjects on any sleep medication since last 3 months
5. Subjects with a history of severe intrinsic sleep related disorders.
6. Subjects who have taken Ashwagandha or any sleep or other supplements within the last three months,
7. People with a known hypersensitivity to Ashwagandha
8. Subjects who work on a night shift
9. Nursing or pregnant women

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: VL-G-A57; Dose: 700mg daily Route: Oral Regimen: 2 capsules in the morning with food and 2 capsules in the evening with food Duration: 60 days	Other: VL-G-A57; Dose: 700mg daily Route: Oral Regimen: 2 capsules in the morning with food and 2 capsules in the evening with food Duration: 60 days
Experimental: VL-G-E12; Dose: 700mg daily Route: Oral Regimen: 2 capsules in the morning with food and 2 capsules in the evening with food Duration: 60 days	Other: VL-G-E12; Dose: 700mg daily Route: Oral Regimen: 2 capsules in the morning with food and 2 capsules in the evening with food Duration: 60 days
Placebo Comparator: Placebo; Dose: 700mg daily Route: Oral Regimen: 2 capsules in the morning with food and 2 capsules in the evening with food Duration: 60 days	Other: Placebo; Dose: 700mg daily Route: Oral Regimen: 2 capsules in the morning with food and 2 capsules in the evening with food Duration: 60 days

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Perceived stress scale	To assess the impact of the Investigational Product (IP) on stress levels by using the Perceived stress scale (PSS)from baseline. Individual scores on the PSS can range from 0 to 40 with higher scores indicating higher perceived stress.; Scores ranging from 0-13 would be considered low stress.; Scores ranging from 14-26 would be considered moderate stress.; Scores ranging from 27-40 would be considered high perceived stress.	Day 0
Perceived stress scale	To assess the impact of the Investigational Product (IP) on stress levels by using the Perceived stress scale (PSS)from baseline. Individual scores on the PSS can range from 0 to 40 with higher scores indicating higher perceived stress.; Scores ranging from 0-13 would be considered low stress.; Scores ranging from 14-26 would be considered moderate stress.; Scores ranging from 27-40 would be considered high perceived stress.	Day 30
Perceived stress scale	To assess the impact of the Investigational Product (IP) on stress levels by using the Perceived stress scale (PSS)from baseline. Individual scores on the PSS can range from 0 to 40 with higher scores indicating higher perceived stress.; Scores ranging from 0-13 would be considered low stress.; Scores ranging from 14-26 would be considered moderate stress.; Scores ranging from 27-40 would be considered high perceived stress.	Day 60

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pittsburgh Sleep Quality Index.	To assess sleep quality using Pittsburgh Sleep Quality Index. In scoring the PSQI, seven component scores are derived, each scored 0 (no difficulty) to 3 (severe difficulty). The component scores are summed to produce a global score (range 0 to 21). Higher scores indicate worse sleep quality.	Day 0, 30 and 60
Restorative sleep questionnaire	To assess change in the total score of the restorative sleep questionnaire weekly RSQ-W is a validated scale for measuring refreshing quality of sleep. It has 9 items with answers scaled from 1 to 5. The questioned asked about one felt after waking up and starting the day during the past seven days. Refer to the questionnaire at Appendix 3 Question 9 is to be reversed scored. The total score is an average score based on all 9 items and rescaled to a 0 to 100 scale, using the following transformation: RSQ-W Total Score = (RSQ-W average score across completed items - 1) X 25. The participants will be asked to administer this scale during screening visit. Those fulfilling the criteria (RSQ-W score ≤ 50), will further fill this scale at day 0, day 30 and day 60 for assessing the efficacy.	Day 0, 30 and 60
Adrenocorticotropic Hormone (ACTH) in plasma	To assess changes in Adrenocorticotropic Hormone (ACTH) in plasma	Day 0, 30 and 60
Morning Salivary Cortisol	To assess changes in morning Salivary Cortisol	Day 0, 30 and 60
Impact of the IP on the Mental alertness	To assess the impact of the IP on the Mental alertness of the participants using a three-pointer scale after rising The scoring will be done as following: 1 = alert, 2 = slightly drowsy and 3 = extremely drowsy	Day 0, 30 and 60
Fatigue Severity Scale	To assess the impact of IP on Fatigue using the Fatigue Severity Scale. The FSS is a self-administered questionnaire with 9 items (questions) investigating the severity of fatigue in different situations during the past week. Grading of each item ranges from 1 to 7, where 1 indicates strong disagreement and 7 indicates strong agreement, and the final score represents the mean value of the 9 items. A visual analogue scale is also included with the scale in which the respondents will be asked to denote the severity of their fatigue at the present moment by placing a mark on a line extending from "no fatigue" to "fatigue as bad as could be." Higher scores on the scale are indicative of more severe fatigue.	Day 0, 30 and 60
Depression, Anxiety, Stress Scale-21	To assess the impact of the IP on total scores of Depression, Anxiety, Stress Scale-21 Higher score indicates worst Depression, Anxiety, Stress.	Day 0, 30 and 60

Collaborators and Investigators

• Sponsor: Vedic Lifesciences Pvt. Ltd.
• Investigators: Principal Investigator: Dr Shalini Srivastava, MD medicine, Vedic Lifesciences Pvt. Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): December 8, 2022
• Primary Completion (Actual): July 12, 2023
• Study Completion (Actual): July 12, 2023

Study Registration Dates

• First Submitted: October 21, 2022
• First Submitted That Met QC Criteria: November 1, 2022
• First Posted (Actual): November 2, 2022

Study Record Updates

• Last Update Posted (Actual): September 6, 2023
• Last Update Submitted That Met QC Criteria: September 4, 2023
• Last Verified: September 1, 2023

More Information

Terms related to this study

• Other Study ID Numbers: GH/220602/A57E12/HPA

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No